Young Jonathan's Form 4 filing
Akero Therapeutics, Inc. (AKRO) · filed Sep 13, 2024
- Accession no.
- 0000950170-24-106473
- Filed
- Sep 13, 2024
- Trade date
- Sep 10, 2024
- Filing delay
- 3 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $14.9K. It was filed 3 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Young JonathanCIK 0001779805 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2024 | Common Stock | SSaleDisposed | −568 | $26.18 | −$14,870.24 | 236,286 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.